Pernix Therapeutics sees Q2 adj EBITDA $4.5-6.0 mln vs loss $1.4 mln year ago and net revs declining 5-10% y/y to $33-35 mln:
- Silenor TRx up 1% in the second quarter of 2017 as compared to the first quarter and down 4% year-over-year. Treximet TRx flat in the second quarter of 2017 as compared to the first quarter and down 7% year-over-year.
- Zohydro ER TRx down 3% in the second quarter of 2017 as compared to the first quarter and down 7% year-over-year; growth rate was impacted by the previously announced 20mg backorder.
No comments:
Post a Comment